



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Nadine Petitpain**

Organisation/Company: Centre Hospitalier Régional Universitaire

Country: France

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
04/2014-09/2022	BOOTS, PIERRE FABRE, HEPATOUM, BIOCDEX, SANOFI,	pholcodine containing products	cough suppression

Classified as public by the European Medicines Agency

BOUCHARA-RECORDATI, GSK, APL BELLS HEALTHCARE, PINEWOOD T and R ERNEST JACKSON
--

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

I currently participate to the steering committee of the institutional clinical trial (ALPHO: Allergy to neuromuscular blocking agents and PHO/codine exposure) that is funded by several pharmaceutical companies. I do not and will not receive any personal gain. The sponsor of this study is the hospital where I work. This study is both observational and interventional. I signed as an investigator but I do not perform patients inclusions in the ALPHO study.

I also ensure the activities of vigilance for clinical trials sponsored by the University Hospital of Nancy from 2006. I do not receive any personal gain from pharmaceutical companies. I am registered in Eudravigilance as user for the CHUNANCY organisation and for the CAVNANCY and CHR Metz-Thionville academic organizations.

I am involved in several data safety monitoring boards of French academic interventional clinical trials, not funded by pharmaceutical companies. I do not receive any fee for this activity.

I work as external expert for the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM).

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Nadine PETITPAIN
Date:	2022-10-27

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template